NewswireToday - /newswire/ -
San Jose, CA, United States, 2008/10/16 - MMPs are key players in normal and pathological processes, including embryogenesis, wound healing, inflammation, arthritis, and cancer.
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling. They are capable of degrading all kinds of extracellular matrix (ECM) proteins, but also can process a number of bioactive molecules. MMPs are key players in normal and pathological processes, including embryogenesis, wound healing, inflammation, arthritis, and cancer.
MMPs share common structural and functional elements and are products of different genes. The three common domains include the pro-peptide, the catalytic domain and the haemopexin-like C-terminal domain linked to the catalytic domain by a flexible hinge region. MMPs are initially synthesized as inactive (latent) zymogens with a pro-peptide domain that must be removed before the enzyme is active.
AnaSpec is pleased to complement its MMP product line with a suite of SensoLyte™ MMP ELISA Kits. These kits are ideal for quantitative detection of MMP proteins (latent and active forms) in serum, plasma, cell culture supernates and urine. The SensoLyte™ ELISA Kits use a convenient, 96-well plate based format with colorimetric read-out.
AnaSpec’s widely used fluorescent SensoLyte™ MMP Activity Assays measure active MMPs in a convenient, 96-well plate-based method with highly sensitive fluorimetric read-out. A colorimetric read-out MMP Activity Assay kit is also available.
AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.